{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:36:43Z","timestamp":1791905803414,"version":"4.3.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Oxford Immunotec USA, Inc","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cytomegalovirus (CMV) infection remains an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients. CMV cell-mediated immunity (CMV-CMI) as determined by a peptide-based enzyme-linked immunospot (ELISPOT) CMV assay may identify patients at risk for clinically significant CMV infection (CS-CMVi).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The CS-CMVi was defined as CMV viremia and\/or disease necessitating antiviral therapy. CMV-CMI was characterized as high when the intermediate-early 1 (IE-1) antigen spot counts (SPCs) were &amp;gt;100 (cutoff 1) or when the IE-1 and phosphoprotein 65 antigen SPCs were both &amp;gt;100 SPCs per 250\u2009000 cells (cutoff 2), and a low CMV-CMI when SPCs were below these thresholds. In this prospective multicenter study, we evaluated CMV-CMI every 2 weeks from the pretransplant period until 6 months posttransplantation in 241 allo-HCT recipients with positive CMV serostatus. The primary endpoint was CS-CMVi occurring within 2 weeks of the last measurement of CMV-CMI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CS-CMVi occurred in 70 allo-HCT recipients (29%). CMV-CMI was low in patients who experienced CS-CMVi (94%), whereas those who had a high CMV-CMI were less likely to have CS-CMVi (P\u2005&amp;lt;\u2005.0001). Patients with CS-CMVi had higher all-cause mortality (P\u2005=\u2005.007), especially those with low CMV-CMI (P\u2005=\u2005.035). On multivariable analysis, CMV-CMI, sex, race, antithymocyte globulin, and steroid use were independent predictors of CS-CMVi, and the time from transplant to engraftment was the only predictor of mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Measurement of CMV-CMI using a novel ELISPOT assay would be useful clinically to monitor allo-HCT recipients and distinguish between those at risk of developing CS-CMVi and requiring antiviral prophylaxis or therapy and those who are protected.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz1210","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T20:08:58Z","timestamp":1577995738000},"page":"2365-2374","source":"Crossref","is-referenced-by-count":92,"title":["Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study"],"prefix":"10.1093","volume":"71","author":[{"given":"Roy F","family":"Chemaly","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"El Haddad","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew J","family":"Winston","sequence":"additional","affiliation":[{"name":"Ronald Reagan UCLA Medical Center , Los Angeles, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Rowley","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center , New Jersey,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M","family":"Mulane","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago , Chicago, Illinois,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranatharthi","family":"Chandrasekar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Wayne State University , Detroit, Michigan,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin K","family":"Avery","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases (Transplant Oncology), Johns Hopkins University , Baltimore, Maryland,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Medical College of Wisconsin , Milwaukee, Wisconsin,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl S","family":"Peggs","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Cancer Institute and University College London Hospitals National Health Service Foundation Trust , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[{"name":"Transplant Infectious Diseases, University Health Network , Toronto, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneesh","family":"Nath","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant, Banner MD Anderson Cancer Center , Gilbert, Arizona,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[{"name":"Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital and Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif B","family":"Mossad","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Respiratory Institute, Cleveland Clinic Foundation , Cleveland, Ohio,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeet S","family":"Dadwal","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, City of Hope , Duarte, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Oxford Immunotec USA, Inc , Charlotte, North Carolina,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimpy P","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of Texas Health , San Antonio, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Ariza-Heredia","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"2024111411413038100_CIT0001","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/338624","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection","volume":"185","author":"Nichols","year":"2002","journal-title":"J Infect Dis"},{"key":"2024111411413038100_CIT0002","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2017.07.025","article-title":"Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring","volume":"23","author":"Yong","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024111411413038100_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review","volume":"342","author":"Ariza-Heredia","year":"2014","journal-title":"Cancer Lett"},{"key":"2024111411413038100_CIT0004","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024111411413038100_CIT0005","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"2024111411413038100_CIT0006","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"2024111411413038100_CIT0007","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/infdis\/jiy592","article-title":"The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients","volume":"219","author":"El Haddad","year":"2019","journal-title":"J Infect Dis"},{"key":"2024111411413038100_CIT0008","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bmt.1705825","article-title":"Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT","volume":"40","author":"Avetisyan","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2024111411413038100_CIT0009","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.bmt.1705507","article-title":"Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation","volume":"38","author":"Avetisyan","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2024111411413038100_CIT0010","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1111\/j.1600-6143.2006.01488.x","article-title":"Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation","volume":"6","author":"Gerna","year":"2006","journal-title":"Am J Transplant"},{"key":"2024111411413038100_CIT0011","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"9","author":"Kumar","year":"2009","journal-title":"Am J Transplant"},{"key":"2024111411413038100_CIT0012","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/bmt.2010.330","article-title":"Reconstitution of CMV pp65 and IE-1-specific IFN-\u03b3 CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT","volume":"46","author":"Tormo","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"2024111411413038100_CIT0013","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/MOT.0b013e3283071463","article-title":"T-cell immune monitoring in organ transplantation","volume":"13","author":"Dinavahi","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"2024111411413038100_CIT0014","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.trre.2004.03.003","article-title":"Use of cytokine enzyme-linked immunosorbent spot (ELISPOT) assay as an immune monitoring tool in solid organ transplantation","volume":"18","author":"Poggio","year":"2004","journal-title":"Transplant Rev"},{"key":"2024111411413038100_CIT0015","first-page":"329","article-title":"Pre-transplant assessment of CMV-specific immune response by ELISPOT assay in kidney transplant recipients","volume":"38","author":"Ritt\u00e0","year":"2015","journal-title":"New Microbiol"},{"key":"2024111411413038100_CIT0016","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"},{"key":"2024111411413038100_CIT0017","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/infdis\/jiw064","article-title":"Utility of the enzyme-linked immunospot interferon-\u03b3-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients","volume":"213","author":"Nesher","year":"2016","journal-title":"J Infect Dis"},{"key":"2024111411413038100_CIT0018","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024111411413038100_CIT0019","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2024111411413038100_CIT0020","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22253","article-title":"The performance of T-cell Xtend reagent in increasing blood storage times for interferon gamma release assays","volume":"32","author":"Li","year":"2018","journal-title":"J Clin Lab Anal"},{"key":"2024111411413038100_CIT0021","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/mpr.124","article-title":"Graphing survival curve estimates for time-dependent covariates","volume":"11","author":"Schultz","year":"2002","journal-title":"Int J Methods Psychiatr Res"},{"key":"2024111411413038100_CIT0022","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12865-017-0195-y","article-title":"An optimized IFN-\u03b3 ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity","volume":"18","author":"Barabas","year":"2017","journal-title":"BMC Immunol"},{"key":"2024111411413038100_CIT0023","doi-asserted-by":"crossref","first-page":"e0193968","DOI":"10.1371\/journal.pone.0193968","article-title":"Assessment of the T-SPOT.CMV interferon-\u03b3 release assay in renal transplant recipients: a single center cohort study","volume":"13","author":"Chanouzas","year":"2018","journal-title":"PLoS One"},{"key":"2024111411413038100_CIT0024","doi-asserted-by":"crossref","first-page":"e0189488","DOI":"10.1371\/journal.pone.0189488","article-title":"Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"2024111411413038100_CIT0025","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/CVI.05633-11","article-title":"Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients","volume":"19","author":"Clari","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"2024111411413038100_CIT0026","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jmv.21727","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital","volume":"82","author":"Fleming","year":"2010","journal-title":"J Med Virol"},{"key":"2024111411413038100_CIT0027","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood.V112.11.4369.4369","article-title":"Quantiferon-CMV for immune-monitoring in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"112","author":"Morello","year":"2008","journal-title":"Blood"},{"key":"2024111411413038100_CIT0028","doi-asserted-by":"crossref","first-page":"e74744","DOI":"10.1371\/journal.pone.0074744","article-title":"Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications","volume":"8","author":"Tey","year":"2013","journal-title":"PLoS One"},{"key":"2024111411413038100_CIT0029","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.hemonc.2017.05.001","article-title":"Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation","volume":"10","author":"Camargo","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2024111411413038100_CIT0030","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2002-11-3472","article-title":"Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation","volume":"102","author":"Hakki","year":"2003","journal-title":"Blood"},{"key":"2024111411413038100_CIT0031","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbmt.2009.07.006","article-title":"Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies","volume":"15","author":"Hamadani","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024111411413038100_CIT0032","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1016\/j.bbmt.2016.12.191","article-title":"Relationship of CMV reactivation and rabbit antithymocyte globulin administration in allogeneic stem cell transplant patients","volume":"23","author":"Kennedy","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024111411413038100_CIT0033","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1182\/blood-2002-05-1387","article-title":"Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells","volume":"100","author":"Ozdemir","year":"2002","journal-title":"Blood"},{"key":"2024111411413038100_CIT0034","doi-asserted-by":"crossref","first-page":"e12929","DOI":"10.1111\/tid.12929","article-title":"Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: outcome and risk factors for late CMV disease","volume":"20","author":"Reusing","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2024111411413038100_CIT0035","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/lt.23540","article-title":"Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience","volume":"18","author":"Wadhawan","year":"2012","journal-title":"Liver Transpl"},{"key":"2024111411413038100_CIT0036","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"2024111411413038100_CIT0037","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz1210\/32522484\/ciz1210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/71\/9\/2365\/34676634\/ciz1210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/71\/9\/2365\/34676634\/ciz1210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:34:21Z","timestamp":1731587661000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/9\/2365\/5740597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,2,20]]},"published-print":{"date-parts":[[2020,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz1210","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2020,2,20]]}}}